Credit Suisse Ag Tcr2 Therapeutics Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$2.11 - $2.94 $33 - $47	16 New	16 $0
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $67,133 - $122,247	-14,658 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $11,925 - $25,928	1,413 Added 10.67%	14,658 $124,000
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $182,544 - $274,874	-11,124 Reduced 45.65%	13,245 $217,000
Q1 2021 May 14, 2021	SELL	$20.38 - $34.07 $207,366 - $346,662	-10,175 Reduced 29.46%	24,369 $538,000
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $656,336 - $1.13 Million	34,544 New	34,544 $1.07 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.